Comments
Shilpa Medicare Ltd has received the US Food and Drug Administration final approval for its ANDA, Erlotinib Tablets, 25 mg, 100 mg, and 150 mg on Tuesday. Erlotinib Tablets, a generic equivalent of reference listed drug Tarceva, used in the treatment of patients with metastatic non-small cell lung cancer and locally advanced, unresectable or metastatic pancreatic cancer as recommended in the label approved by FDA.
According to IQVIA MAT Q2 2019 data, the US market for Erlotinib Tablets is approximately $172 million. The stock of Shilpa Medicare closed flat at ₹310 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.